Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
GP has held a final close short of its initial €800m target, following a challenging fundraise
Deal for luxury catering company marks the first investment by Livingbridge's sixth fund
RSK received £33m of debt funding from Permira Debt Managers in 2015
Clessidra reaped a 3x money return following a 17-month holding period